標(biāo)題: Titlebook: Immunotherapy of Cancer; Mary L. Disis Book 2006 Humana Press 2006 Antigen.T cell.cell.cell therapy.clinical trial.cytokine.cytokines.imag [打印本頁] 作者: Menthol 時(shí)間: 2025-3-21 16:45
書目名稱Immunotherapy of Cancer影響因子(影響力)
書目名稱Immunotherapy of Cancer影響因子(影響力)學(xué)科排名
書目名稱Immunotherapy of Cancer網(wǎng)絡(luò)公開度
書目名稱Immunotherapy of Cancer網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Immunotherapy of Cancer被引頻次
書目名稱Immunotherapy of Cancer被引頻次學(xué)科排名
書目名稱Immunotherapy of Cancer年度引用
書目名稱Immunotherapy of Cancer年度引用學(xué)科排名
書目名稱Immunotherapy of Cancer讀者反饋
書目名稱Immunotherapy of Cancer讀者反饋學(xué)科排名
作者: 做方舟 時(shí)間: 2025-3-21 20:30 作者: Essential 時(shí)間: 2025-3-22 04:06
Tumor-Reactive T-Cells for Adoptive Immunotherapy, spontaneous.” As these trials are not solely conducted for treating cancer patients, but also for research on human beings, the resulting scientific observations have increased our understanding of T-cell activation, homing, and survival, as well as of the possibility of disrupting regulatory mecha作者: 金絲雀 時(shí)間: 2025-3-22 07:16 作者: Pde5-Inhibitors 時(shí)間: 2025-3-22 11:45 作者: 注意力集中 時(shí)間: 2025-3-22 15:18
Tumor-Induced Immune Suppression and Immune Escape,c profile of tumor cells because of their genetic instability. These topics are reviewed in this chapter, following a brief description of the essential components of a TA-specific immune response. Lastly, potential strategies to counteract tumor immune suppression and immune escape mechanisms are d作者: ovation 時(shí)間: 2025-3-22 19:45
Manipulation of Lymphocyte Homeostasis for Enhancing Antitumor Immunity,ive antitumor responses have been unsuccessful to control disease because of inadequate T-cell activation, the fleeting duration of antitumor T-cell responses, and an active suppressor system that downplay immune responses.作者: Axon895 時(shí)間: 2025-3-22 21:38
di- cal school clinical practice situation, I set aside one day each week to puzzle over the theoretical questions that my clinical experience gener- ates. Often isolating these underlying theoretical questions provides guidance into the most relevant empirical literature. I have found that this wee作者: 線 時(shí)間: 2025-3-23 03:01
?zlem Türeci MD,Thorsten Klamp PhD,Michael Koslowski MD,Sebastian Kreiter MD,Ugur Sahin MDy in my medi- cal school clinical practice situation, I set aside one day each week to puzzle over the theoretical questions that my clinical experience gener- ates. Often isolating these underlying theoretical questions provides guidance into the most relevant empirical literature. I have found that this wee978-1-4757-9708-4978-1-4757-9706-0作者: 恫嚇 時(shí)間: 2025-3-23 06:41
Ludmila Müller PhD,Stephanie McArdle PhD,Evelyna Derhovanessian DIPL BIOL,Thomas Flad PhD,Ashley Knie-style and behavioral factors, such as diet, smoking, and exercise, are major risk factors for the prevention of these disorders. With the chronicity of disease, behavioral factors become even more crucial to prognosis and to effective therapy (compliance with medication, depression, etc.). In 1979作者: LAITY 時(shí)間: 2025-3-23 11:57
Weiping Zou MD, PhD,Tyler J. Curiel MD, MPHy transfusion, perhaps augmented by the effects of hemorrhage, anesthesia, and surgical stress..The most likely mechanism underlying transfusion-induced immunosuppression is anergy due to presentation of large amounts of antigen through the intravenous route. This favors presentation of antigen by “作者: Corroborate 時(shí)間: 2025-3-23 14:43
Noweeda Mirza PhD,Dmitry Gabrilovich MD, PhDroducts is the standard of practice for the situation where the donor and recipient are related. Cytomegalovirus infection in neonatal blood recipients remains a significant risk and studies have increasingly suggested that this may be prevented by pre-storage or blood bank filtration under controll作者: ILEUM 時(shí)間: 2025-3-23 20:52 作者: AXIOM 時(shí)間: 2025-3-23 22:38
Jie Dai MD,Zihai Li MD, PhDtroductory chapter that gives a general overview of the various aspects of the clinical biochemistry of these disorders, while the closing chapter deals with an important aspect that deserves to be increasingly emphasized in laboratory medicine, i.e., strategies to integrate information coming from 作者: 神圣不可 時(shí)間: 2025-3-24 03:20
Helga Bernhard MD,Julia Neudorfer,Kerstin Gebhard,Heinke Conrad BS,Dirk H. Busch,Christian Peschel M作者: 情感脆弱 時(shí)間: 2025-3-24 08:12 作者: Panther 時(shí)間: 2025-3-24 12:08
Leisha A. Emens MD, PhD,R. Todd Reilly PhD,Elizabeth M. Jaffee MD作者: Amendment 時(shí)間: 2025-3-24 17:34 作者: 意外的成功 時(shí)間: 2025-3-24 19:47
DNA Vaccines for Cancer Immunotherapy,hods currently available for constructing DNA vaccines and the implications for cancer therapy will be reviewed. Finally, some of the safety and ethical concerns generated by DNA vaccination are presented.作者: Ledger 時(shí)間: 2025-3-25 01:57 作者: Ophthalmoscope 時(shí)間: 2025-3-25 05:02 作者: Cumbersome 時(shí)間: 2025-3-25 08:16
Retroviral-Mediated Gene Transfer for Engineering Tumor-Reactive T-Cells,heral blood T-cells. By cloning genes for T-cell receptors that mediate antitumor reactivity and introducing them into a patient’s own T-cells, we can rapidly generate the large number of T-cells necessary for adoptive transfer therapy for any patient, regardless of the patient’s immune status.作者: Essential 時(shí)間: 2025-3-25 14:41 作者: LARK 時(shí)間: 2025-3-25 19:03
Book 2006in clinical trial design, the need for biomarkers of response-such as novel imaging techniques and immunologic monitoring-and the new advances and directions in cancer immunotherapy are also fully examined.作者: 的染料 時(shí)間: 2025-3-25 22:25
2196-9906 aptive and innate immunity. The challenges in clinical trial design, the need for biomarkers of response-such as novel imaging techniques and immunologic monitoring-and the new advances and directions in cancer immunotherapy are also fully examined.978-1-61737-645-0978-1-59745-011-9Series ISSN 2196-9906 Series E-ISSN 2196-9914 作者: 苦笑 時(shí)間: 2025-3-26 03:38 作者: Adrenal-Glands 時(shí)間: 2025-3-26 06:51 作者: Pelvic-Floor 時(shí)間: 2025-3-26 08:43
The Tumor Microenvironment,e tumor microenvironment modulates the immune response is vital to designing new potential ways of boosting anticancer immunity. This chapter is focused on providing a rationale for new prospects of manipulating the tumor microenvironment to minimize escape from natural anticancer immune response and targeted immunotherapies.作者: 水土 時(shí)間: 2025-3-26 13:55
Fast-Lane Evolution in the Tumor Microenvironment,through secretion of factors that may influence the function of the arm of the innate or adaptive immune response. We describe novel technologies that could be applied for the study in real time of these phenomena directly in humans.作者: Engaged 時(shí)間: 2025-3-26 17:04 作者: OTHER 時(shí)間: 2025-3-26 23:23 作者: incarcerate 時(shí)間: 2025-3-27 04:52
Discovery of Target Molecules for Cancer Immunotherapy by Genetic and Bioinformatic Approaches, them against target molecules expressed selectively on tumor cells. Different genetic approaches for discovery of such target candidates have been developed over the last 15 yr and are being pursued. The classical approaches apply expression cloning using either cancer-reactive T-lymphocytes or aut作者: 尖牙 時(shí)間: 2025-3-27 08:08 作者: Compassionate 時(shí)間: 2025-3-27 12:06 作者: output 時(shí)間: 2025-3-27 15:56
The Role of Immune Monitoring in Evaluating Cancer Immunotherapy,tended to induce. In this chapter, current cellular immune monitoring methods will be reviewed briefly in an effort to compare and contrast their utility. These methods include cytotoxicity and proliferation assays (radioactive and nonradioactive), cytokine assays (bulk and singlecell assays), and m作者: 維持 時(shí)間: 2025-3-27 20:32 作者: 鋸齒狀 時(shí)間: 2025-3-27 22:04 作者: FIS 時(shí)間: 2025-3-28 04:22 作者: motivate 時(shí)間: 2025-3-28 07:38
Different Approaches to Dendritic Cell-Based Cancer Immunotherapy,We discuss requirements for tumor-associated antigens, antigen carriers, and selection of patients. Theoretical considerations are supported by specific experiments testing p53 vaccine in preclinical settings in vitro and in vivo.作者: 替代品 時(shí)間: 2025-3-28 12:13
Anti-Idiotype Antibody Vaccines for the Immunotherapy of Cancer,nd functions of the external antigens and can be used as surrogate antigens for active specific immunotherapy. Several monoclonal anti-Id antibodies that mimic distinct human tumor-associated antigens have been developed and characterized by others and us. CeaVac (anti-Id 3H1) is an internal image a作者: carotid-bruit 時(shí)間: 2025-3-28 17:48
Autologous Tumor-Derived Heat Shock Protein Vaccine as a New Paradigm for Individualized Cancer The induced in response to the accumulation of misfolded proteins in the cell. They are essential in chaperoning proteins and maintaining the correct conformation of protein substrates. Recently, these molecules have been implicated in bridging innate and adaptive immunity, owing to their ability to ch作者: 地名詞典 時(shí)間: 2025-3-28 20:36 作者: 階層 時(shí)間: 2025-3-29 02:26 作者: appall 時(shí)間: 2025-3-29 06:14 作者: Nomadic 時(shí)間: 2025-3-29 07:26 作者: 拒絕 時(shí)間: 2025-3-29 14:34
Tumor-Induced Immune Suppression and Immune Escape,ression in patients with malignant disease. These findings have provided the rationale for the development of active specific immunotherapy for the treatment of malignant disease. The enthusiastic application of active specific immunotherapy in a large number of patients has conclusively shown that:作者: 懶鬼才會(huì)衰弱 時(shí)間: 2025-3-29 16:55
The Tumor Microenvironment,ingly clear. Survival and expansion of tumor cells cannot be achieved in the absence of a favorable microenvironment, the main components of which are leukocytes, vascular cells, and fibroblasts. This tumor microenvironment critically provides growth factors and survival signals for tumor cell proli作者: FLAGR 時(shí)間: 2025-3-29 21:06 作者: MAG 時(shí)間: 2025-3-30 01:42
Fast-Lane Evolution in the Tumor Microenvironment,une system to those related to the genetic instability of cancer cells. We have discussed elsewhere the relevance of immune polymorphism and immune adaptation to the study of tumor host interactions in the tumor microenvironment. In this chapter, we describe changes occurring during the natural hist作者: collagenase 時(shí)間: 2025-3-30 07:03
Manipulating Immunological Checkpoints to Maximize Antitumor Immunity,nto clinically meaningful tumor regressions, particularly in advanced disease. It is increasingly clear that tumor-specific immune tolerance represents a layered system of controls that keep the immune system turned off. Immunoregulatory checkpoints map locoregionally to the tumor microenvironment a作者: 基因組 時(shí)間: 2025-3-30 09:25
ables to physiological variables. My primary emphasis is on what psychological and behavioral concepts and procedures are most likely to enable us to influence physiological functions. The book covers ques- tions that have fascinated me and with which I have struggled in daily clinical practice. Wha作者: 安裝 時(shí)間: 2025-3-30 15:18 作者: intertwine 時(shí)間: 2025-3-30 20:22
Ludmila Müller PhD,Stephanie McArdle PhD,Evelyna Derhovanessian DIPL BIOL,Thomas Flad PhD,Ashley Kni of the inadequacies of conventional medical treatments for these disorders. Acute infectious diseases, like pneumonia and tuberculosis, no longer kill or cripple citizens of the United States so frequently as they did in 1900. Instead, chronic stress-related multifactorial conditions, like cardiova作者: 內(nèi)向者 時(shí)間: 2025-3-30 22:48 作者: delegate 時(shí)間: 2025-3-31 04:11 作者: 消息靈通 時(shí)間: 2025-3-31 06:52
Malaya Bhattacharya-Chatterjee PhD,Nitin Rohatgi MD,Sunil K. Chatterjee PhD,Asim Saha PhD,Rakesh Shuation that provides a comprehensive collection of the various leading aspects that go to make up this complex theme. Therefore, we thought it useful to gather together a few scientists whose work has focused on the various clinical biochemistry-aspects of these disorders in order that they might dis作者: capsule 時(shí)間: 2025-3-31 09:39 作者: Cursory 時(shí)間: 2025-3-31 13:39
Mary L. DisisIncludes supplementary material: 作者: 和藹 時(shí)間: 2025-3-31 20:42
Cancer Drug Discovery and Developmenthttp://image.papertrans.cn/i/image/462307.jpg作者: Costume 時(shí)間: 2025-4-1 01:33
https://doi.org/10.1385/1597450111Antigen; T cell; cell; cell therapy; clinical trial; cytokine; cytokines; imaging; imaging techniques; immuno作者: Disk199 時(shí)間: 2025-4-1 02:50
